Compare TKO & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TKO | NBIX |
|---|---|---|
| Founded | 1980 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 13.2B |
| IPO Year | N/A | 1996 |
| Metric | TKO | NBIX |
|---|---|---|
| Price | $202.67 | $132.20 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 17 | 21 |
| Target Price | ★ $223.25 | $177.05 |
| AVG Volume (30 Days) | 902.8K | ★ 1.1M |
| Earning Date | 02-25-2026 | 02-05-2026 |
| Dividend Yield | ★ 1.53% | N/A |
| EPS Growth | N/A | ★ 12.44 |
| EPS | 1.85 | ★ 4.19 |
| Revenue | $2,545,175,000.00 | ★ $2,682,700,000.00 |
| Revenue This Year | $69.88 | $23.59 |
| Revenue Next Year | $29.58 | $18.65 |
| P/E Ratio | $109.58 | ★ $31.58 |
| Revenue Growth | N/A | ★ 19.61 |
| 52 Week Low | $133.07 | $84.23 |
| 52 Week High | $218.11 | $160.18 |
| Indicator | TKO | NBIX |
|---|---|---|
| Relative Strength Index (RSI) | 46.20 | 35.61 |
| Support Level | $197.95 | $131.30 |
| Resistance Level | $213.02 | $135.98 |
| Average True Range (ATR) | 4.82 | 3.27 |
| MACD | -1.00 | -0.68 |
| Stochastic Oscillator | 21.62 | 8.58 |
TKO Group Holdings Inc is a sports and sports entertainment company that operates combat sports and sports entertainment companies. It owns and manages valuable sports and entertainment intellectual property. The company distributes content and monetizes its intellectual property through four principal activities: Media Rights and Content, Live Events, Sponsorship, and Consumer Products Licensing. The company has two reportable segments, UFC and WWE. The company generates majority of revenue from the UFC segment. The UFC segment revenue consists of media rights fees associated with the distribution of its programming content, ticket sales, and site fees associated with the business's international live events, sponsorship, and consumer products licensing agreements of UFC-branded products.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.